Clinical Data Key pipeline drug for Lundbeck delivers in Cushing syndrome PharmaphorumLundbeck has reported positive trial results with Cushing's therapy asedebart, a key R D prospect as it faces a patent cliff in the next few years.Rare DiseaseRead full story pharminent June 15, 2026 (Last updated: June 15, 2026) Pharmaphorum Lundbeck has reported positive trial results with Cushing’s therapy asedebart, a key R D prospect as it faces a patent cliff in the next few years. Rare Disease Read full story Post navigation Previous: Rhythm’s obesity drug scores ‘better than expected’ weight loss in rare genetic diseaseNext: Eisai claims UK grant to expand manufacturing site Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
